证券代码：301371 证券简称：敷尔佳 公告编号：2025-037 哈尔滨敷尔佳科技股份有限公司 第二届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、审议通过《关于聘任财务负责人的议案》 经董事会审查，李政德先生具备担任财务负责人相应的专业知识与工作经验， 具备担任上市公司财务负责人的能力，任职资格符合上市公司财务负责人的任职条 件，不存在《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》《公司章程》中规定禁止任职的条件，不存在损害公司及其他 股东特别是中小股东利益的情形。同意聘任李政德先生为公司财务负责人，任期自 本次董事会审议通过之日起至第二届董事会届满之日止。 具体内容详见公司同日刊登在巨潮资讯网（www.cninfo.com.cn）上的相关公告。 表决结果：同意 6 票，反对 0 票，弃权 0 票。 本议案已经公司董事会审计委员会、提名委员会审议通过。 2、审议通过《关于制定<子公司管理制度>的议案》 一、董事会会议召开情况 哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）第二届董 ...

Market Overview - On September 25, the cosmetics sector declined by 0.34%, with Jiaheng Jiahua leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Individual Stock Performance - Notable gainers included: - Jinsheng New Material (300849) with a closing price of 13.42, up 1.82% [1] - Tiancaiya (603605) with a closing price of 80.50, up 1.31% [1] - Major decliners included: - Jiaheng Jiahua (300955) with a closing price of 27.90, down 2.04% [2] - Wanmei Biological (603983) with a closing price of 39.81, down 1.87% [2] Trading Volume and Capital Flow - The cosmetics sector experienced a net outflow of 49.89 million yuan from main funds, while retail investors saw a net inflow of 29.38 million yuan [2] - The trading volume for key stocks included: - Shanghai Jahwa (600315) with a trading volume of 37,100 shares and a turnover of approximately 96.45 million yuan [1] - Qingdao Kingway (002094) with a trading volume of 167,200 shares and a turnover of approximately 130 million yuan [2] Fund Flow Analysis - Main fund inflows and outflows for selected stocks: - Shanghai Jahwa had a main fund net inflow of 3.17 million yuan, while retail investors contributed a net inflow of 3.43 million yuan [3] - Jiaheng Jiahua saw a main fund net outflow of 393,800 yuan, with retail investors contributing a net outflow of 387,720 yuan [3]

Core Viewpoint - The company is focusing on enhancing its research and development capabilities by leveraging talent from Harbin Institute of Technology and expanding its R&D teams in multiple locations [1] Group 1: R&D Strategy - The company has established R&D centers in Harbin and Shanghai, creating a collaborative research system [1] - The current scale of the R&D team is steadily expanding, with ongoing efforts to build a core technical talent pipeline [1] - Future plans include increasing the recruitment and training of high-end R&D talent to improve team expertise and innovation capabilities [1] Group 2: Development Goals - The company aims to strengthen its core R&D capabilities to support technological breakthroughs and product iterations [1] - Suggestions from investors will be considered in the company's development strategy to promote high-quality growth of the R&D system [1]

Core Viewpoint - The company Fuhua Jia experienced a decline in stock price and trading volume, with significant changes in financing and shareholder structure, indicating potential challenges in its financial performance and market position [1][2][3]. Financing Summary - On September 23, Fuhua Jia's stock price fell by 2.12%, with a trading volume of 47.50 million yuan. The financing buy-in amount was 4.99 million yuan, while the financing repayment was 7.16 million yuan, resulting in a net financing buy-in of -2.16 million yuan. The total financing and securities balance reached 101 million yuan [1]. - The current financing balance of 101 million yuan accounts for 5.12% of the circulating market value, which is below the 20th percentile level over the past year, indicating a low financing level [1]. - In terms of securities lending, Fuhua Jia repaid 300 shares and sold 3,700 shares on September 23, with a selling amount of 90,700 yuan. The remaining securities lending volume was 15,700 shares, with a balance of 384,500 yuan, which is above the 70th percentile level over the past year, indicating a high level [1]. Financial Performance Summary - For the first half of 2025, Fuhua Jia reported an operating income of 863 million yuan, a year-on-year decrease of 8.15%. The net profit attributable to the parent company was 230 million yuan, down 32.54% year-on-year [2]. - Since its A-share listing, Fuhua Jia has distributed a total of 1 billion yuan in dividends [3]. Shareholder Structure Summary - As of September 19, the number of shareholders for Fuhua Jia was 15,000, a decrease of 5.99% from the previous period. The average circulating shares per person increased by 6.37% to 5,166 shares [2]. - As of June 30, 2025, among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF ranked as the second-largest shareholder with 2.55 million shares, an increase of 655,700 shares from the previous period. New entrants included Guangfa Pension Index A and Huaxia Zhongzheng 1000 ETF [3].

证券日报网讯敷尔佳（301371）9月23日发布公告，在公司回答调研者提问时表示，销售渠道优化工作 是持续、动态开展的，上半年已取得阶段性进展，销售渠道逐渐回归健康，今年第二季度营业收入环比 增长86.68%，业绩呈回暖趋势，进展符合公司预期。 ...

Core Viewpoint - The company, Fulejia, announced on September 23 that its products are primarily divided into two categories: medical devices and functional skincare products, featuring a diverse range of formulations including masks, waters, serums, lotions, sprays, single-use products, and eye masks [2] Group 1 - The company offers a wide variety of product forms, which enhances its market coverage [2] - The product categories include both medical devices and functional skincare, indicating a diversified product portfolio [2]

Group 1 - The core viewpoint of the article highlights the successful collaboration between the company and JD.com, which has led to a significant increase in product variety on JD's platform [2] - The company has implemented new cooperative strategies such as promotional activities and new product launches, contributing to JD.com's growth [2] - The announcement was made during a response to inquiries from researchers, emphasizing the positive performance observed in the first half of the year [2]

Core Viewpoint - The company, Fuhua, announced on September 23 that it has completed all three rounds of clinical trials for its recombinant human collagen freeze-dried fiber project, and is currently in the data cleaning and report preparation phase, progressing smoothly and in line with company expectations [2] Group 1 - The company has successfully completed the three rounds of injections for the clinical trial [2] - The project is now in the data cleaning and summary report preparation stage [2] - The progress of the project is satisfactory and meets the company's expectations [2]

Core Insights - The company, Fulejia, reported strong sales performance for its lactose acid masks in the first half of the year, aligning with its expectations [2] Company Summary - Fulejia announced on September 23 that the sales data for its lactose acid masks was very positive, meeting the company's forecasts [2]

Group 1: Sales Performance - The company's sales channel optimization has shown significant progress, with a 86.68% increase in revenue from Q1 to Q2 2025, indicating a recovery trend that aligns with company expectations [1] - The lactose acid mask launched in August last year has performed very well in sales during the first half of 2025, meeting company expectations [2] Group 2: Product Structure and Development - The company's product range includes medical devices and functional skincare products, featuring various forms such as masks, essences, lotions, and sprays [1] - The company has a robust pipeline of research projects, with ongoing efforts to enhance R&D capabilities following the establishment of a new R&D center in Shanghai [2] Group 3: Online Sales Channels - JD.com has emerged as a strong online sales channel, with the company enhancing its collaboration with JD to diversify product offerings and implement new promotional strategies, resulting in notable growth on the platform [2] Group 4: Future Plans - The company plans to continue launching new products in the upcoming quarters, with specific details to be announced in future communications [2] - Dividend arrangements for the third quarter are still under consideration, with updates to be provided through official announcements [2]